• A Bead-Based Nonradioactive Immunoassay for Autoantibody Testing in a Mouse Model of Myasthenia Gravis
• A Case of Congenital Myasthenia Gravis due to ChAT Gene Mutation in a Term Neonate: A Case Report
• A case report of elevated bromide levels from pyridostigmine bromide for treatment of myasthenia gravis
• A class of chemical compounds enhances clustering of muscle nicotinic acetylcholine receptor in cultured myogenic cells
• A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma
• A mendelian randomization study investigating the causal relationships between 1400 serum metabolites and autoimmune diseases
• A new pragmatic classification system for thymoma associated myasthenia gravis: a retrospective cohort study
• A perplexing case report of concomitant multiple sclerosis and myasthenia gravis
• A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
• A short-term functional recovery comparison of therapeutic plasma exchange and immunoadsorption in severe acute neuroimmune diseases
• Advancements and challenges in CAR T cell therapy in autoimmune diseases
• Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
• An unusual initiation of an ocular form of MuSK-positive myasthenia gravis after magnesium administration: a rare case report
• Anti-alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Antibody Encephalitis in an Immunosuppressed Patient With Myasthenia Gravis Post-thymoma Treatment
• Anti-AMPA receptor encephalitis with myasthenia gravis: A sinister combination associated with a high risk for underlying malignancy
• Application of Digital Tools and Artificial Intelligence to the Myasthenia Gravis Core Examination
• Application of Electrophysiological Techniques in Assessing of Neuromuscular Junction-Related Disorders
• Atypical Thymoma (WHO Type B3) with Prominent Microcystic and Mucoid Changes Mimicking Thymic Mucoepidermoid Carcinoma: A Clinicopathological and Immunohistochemical Study of Five Cases
• Autoimmune autonomic ganglionopathy and myasthenia gravis: a case report and review of the literature
• Azathioprine and mycophenolate mofetil in myasthenia gravis
• Azathioprine and mycophenolate mofetil in myasthenia gravis - Authors' reply
• Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
• Case report: A patient with brachio-cervical inflammatory myopathy was misdiagnosed as flail arm syndrome
• Characterization of Clinical Phenotypes in Congenital Myasthenic Syndrome Associated with the c.1327delG Frameshift Mutation in CHRNE Encoding the Acetylcholine Receptor Epsilon Subunit
• Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis
• Clinical features of thymoma with and without myasthenia gravis
• Comparative Analysis of Serum Amino Acid Profiles in Patients with Myasthenia Gravis and Multiple Sclerosis
• Compassionate Ventilator Release in Patients With Neuromuscular Disease: A Two-Case Comparison
• Concordance between radioimmunoassay and fixed cell-based assay in subjects without myasthenia gravis: optimizing the diagnostic approach
• Cooccurrence of Myasthenia Gravis and Epilepsy: A Case Report
• Correction: Thymoma resection and myasthenia gravis: what is the neurological outcome in patients older than 65 years?
• Correlation between neuropsychiatric systemic lupus erythematosus and immunological markers: a real-world retrospective study
• Decoding myasthenia gravis: advanced diagnosis with infrared spectroscopy and machine learning
• Delayed Diagnosis of Thymoma in Ocular Myasthenia Gravis
• Diagnostic accuracy of voluntary and stimulated neuromuscular jitter studies in ocular myasthenia gravis
• Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4(+) T cells and modulating gut microbiota
• Disseminated infection caused by Nocardia cyriacigeorgica in immunocompromised patient confirmed by whole genome sequencing
• Diurnal cognitive functioning in patients with myasthenia gravis with the role of chronotype and depression: a pilot study
• Effect of Follicular T helper and T helper 17 cells-related Molecules on Disease Severity in Patients with Myasthenia Gravis
• Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study
• Efficacy and Safety of Rescue Treatment with Plasma Exchange in Patients with Acute Inflammatory Neurological Disorders: A Single Center Experience
• Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series
• Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series
• Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report
• Efgartigimod Successfully Ameliorated Acute Exacerbation of Myasthenia Gravis with Anti-muscle-specific Kinase Antibodies
• Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review
• Experience of using eculizumab in refractory myasthenia gravis
• Exploring the Roles of m6A-Modified circRNAs in Myasthenia Gravis Based on Multi-Omics Analysis
• Fiber endoscopic evaluation of swallowing (FEES) - an important tool for diagnosing myasthenia gravis
• FOSL1-mediated LINC01566 negatively regulates CD4(+) T-cell activation in myasthenia gravis
• Frequency and severity of autonomic dysfunction assessed by objective hemodynamic responses and patient-reported symptoms in individuals with myasthenia gravis
• Helminth derivative tuftsin-phopshorylcholine, to treat autoimmunity
• HSCT for stiff person syndrome and myasthenia gravis
• IFN-α2 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections
• Insights from CD71 presentation and serum lipid peroxidation in myasthenia gravis - A small cohort study
• Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra-Rare Disease Therapeutics
• Isolated ipsilateral ptosis associated with ventral midbrain infarction: a case report and literature review
• Management of apixaban anticoagulation in a patient requiring therapeutic plasma exchange: a case report and a literature review
• Myasthenia gravis
• Myasthenia gravis Lambert-Eaton overlap syndrome: Recommended modification for the diagnostic criteria
• Myasthenia gravis: the future is here
• Neurologic disease in the obstetric patient
• Neuromyotonia
• Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database
• No sex-based differences in odds of starting or time to treatment of generalized myasthenia gravis: A single center cohort study
• Paraneoplastic neurological syndromes of small cell lung cancer
• Pembrolizumab-induced Myasthenia Gravis and Myocarditis
• Pembrolizumab-induced myasthenia gravis: Two patients' experiences
• Possible sex and racial disparities in myasthenia gravis care
• Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis
• Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective
• Prognostic significance of preoperative creatine kinase in resected thymic epithelial tumors
• Progressive Multifocal Leukoencephalopathy in Myasthenia Gravis With Selective Hypogammaglobulinemia
• Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets
• Rituximab Therapy for Immune-Mediated Neurological Diseases: Our Experience at a Tertiary Care Centre
• Robotic-assisted Extended Thymectomy for Large Resectable Thymoma: 21 Years' Experience
• Serological indication of chronic inflammatory demyelinating polyneuropathy as an extrahepatic manifestation of hepatitis E virus infection
• Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring
• Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls
• Single simple question in axonal polyneuropathy
• Spatial transcriptomics elucidates medulla niche supporting germinal center response in myasthenia gravis-associated thymoma
• Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity
• Sustained Response of Ibrutinib in a Patient with Waldenstrom Macroglobulinemia Presenting with Myasthenic Crisis as a Paraneoplastic Neurological Syndrome: A Case Report and Review of Literature
• Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
• Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis
• The Application Potential of the Regulation of Tregs Function by Irisin in the Prevention and Treatment of Immune-Related Diseases
• The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms
• The impact of diagnosis delay on European patients with generalised myasthenia gravis
• The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases
• The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series
• The speed of completion of the decremental responses on repetitive nerve stimulation
• Therapeutic Approach to Autoimmune Neurologic Disorders
• Thoracoscopic removal of cranial mediastinal masses in dogs is associated with a low conversion rate, excellent survival to discharge, and good long-term outcome
• Thoracoscopic thymectomy for myasthenia gravis and non-invasive thymoma after COVID-19 pneumonia
• United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
• Use of a novel configuration of ports for patients needing intermittent long-term apheresis
• Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis
• Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study
• Weighted gene coexpression network analysis and machine learning for the determination of tfh cell and B cell infiltrating biomarkers in thymoma-associated myasthenia gravis
• Worsening of myasthenic symptoms associated with statins